Proteome Sciences (LSE:PRM) FCF Margin % : -88.61% (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Proteome Sciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Proteome Sciences's Free Cash Flow for the six months ended in Dec. 2023 was £-1.61 Mil. Proteome Sciences's Revenue for the six months ended in Dec. 2023 was £1.82 Mil. Therefore, Proteome Sciences's FCF Margin % for the quarter that ended in Dec. 2023 was -88.61%.

As of today, Proteome Sciences's current FCF Yield % is -6.30%.

The historical rank and industry rank for Proteome Sciences's FCF Margin % or its related term are showing as below:

LSE:PRM' s FCF Margin % Range Over the Past 10 Years
Min: -219.41 Med: -15.47 Max: 33.03
Current: -14.28

During the past 13 years, the highest FCF Margin % of Proteome Sciences was 33.03%. The lowest was -219.41%. And the median was -15.47%.

LSE:PRM's FCF Margin % is ranked worse than
52.04% of 221 companies
in the Medical Diagnostics & Research industry
Industry Median: -11.47 vs LSE:PRM: -14.28

Proteome Sciences FCF Margin % Historical Data

The historical data trend for Proteome Sciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Proteome Sciences FCF Margin % Chart

Proteome Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-0.82

33.03

11.48

23.41

-14.28

Proteome Sciences Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial															19.46	29.60	18.98	27.82	-88.61

Competitive Comparison of Proteome Sciences's FCF Margin %

For the Diagnostics & Research subindustry, Proteome Sciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Proteome Sciences's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Proteome Sciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Proteome Sciences's FCF Margin % falls into.

Proteome Sciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Proteome Sciences's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-0.718	/	5.028
	=	-14.28 %

Proteome Sciences's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-1.611	/	1.818
	=	-88.61 %

Proteome Sciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of Proteome Sciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Proteome Sciences (LSE:PRM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Proteome Sciences PLC (LSE:PRM) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

PMSNF:USA PRM.GB:UK PI2:Germany

Address

Downside Bridge Road, Coveham House, Cobham, Surrey, GBR, KT11 3EP

Website

https://www.proteomics.com

Proteome Sciences PLC is protein biomarker research and development. The company uses high sensitivity proprietary techniques to detect and characterize differentially expressed proteins in diseases for diagnostic, prognostic and therapeutic applications. Its only reportable segment is the sale of goods and biomarker services. It generates maximum revenue from the TMT product. Geographically, it has a presence in the United States, the United Kingdom, and the European Union.